P202 AS A Potential Therapeutic Gene for Breast Cancer
Abstract
The main goal of this proposal is to study the anti-tumor activity of p202 and its application in a breast cancer model system. Three specific aims are 1) To determine the effects of p2O2 on the sensitivity of breast cancer%%cells to anticancer agents; 2) To test the anti-tumor activity of p202 in breast cancer cells using preclinical gene therapy strategies in an orthotopic breast cancer animal model; and 3) To evaluate the therapeutic efficacy of p202 gene therapy in combination with other anti-cancer agents in an orthotopic breast cancer animal model. We have completed the first two aims in the funding period. However, In an attempt to develop the p202 gene as a therapeutic gene for human clinical trials, we initiated a communication with FDA and were told that the p202 gene is of mouse origin and it is not favorable for human clinical trials. Hence, we turn our attention to the human 200 family members in a hope to identify a human gene associates with a strong anti-cancer activity as p202 does. To this end, we found that growth arrest of AIM2 is comparable to that of p202. Therefore, in the current status, we intend to further characterize the anti-cancer activity and therapeutic efficacy of AIM2 gene in vitro and in vivo, and to develop a gene therapy protocol using AIM2 as a therapeutic gene for breast cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2004
- Accession Number
- ADA425540
Entities
People
- Mien-Chie Hung
Organizations
- The University of Texas MD Anderson Cancer Center